Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
CDC25B antibody was raised against recombinant human M-phase inducer phosphatase 2 protein (1-195AA)
Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity.
PBS, pH 7.4, 0.03% Proclin 300, 50% glycerol.
Short term: -20°C; Long term: -80°C; Avoid freeze-thaw cycles.
CDC25B, a CDC25 dual specificity protein phosphatase, has been shown to affect cell cycle regulation by activating cyclin-dependent kinases Cdk1 and Cdk2 during G2 phase. CDC25B also has been shown to possess oncogenic properties and has been implicated in lung, breast, esophagus, stomach, ovarian, and other cancers. Recently CDC25B has been shown to be a steroid receptor coactivator and this function is independent of the protein phosphatase activity in vitro.